Hympavzi® (marstacimab-hncq)
for Hemophilia

Hympavzi (marstacimab-hncq) is a once-weekly subcutaneous treatment for adults and children aged 12 and older with hemophilia A or B without inhibitors. It works by targeting the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), reducing its anticoagulant effect to promote blood clot formation. Hympavzi offers a new management option for hemophilia, especially for those who develop inhibitors to factor VIII or IX.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Hemophilia